MASCC 2024 – #2633 Real-world Deployment of Patient Monitoring in Oncology Care Centers in France: a Full Retrospective Analysis (ARGOS) 772 Healthcare

Charles Parnot^{1†}, Trevor Stanbury², Nicolas Bégin¹, François-Guirec Champoiseau¹ 1. Cureety, Dinan 2. Pro-Pens Antony † corresponding author charles@cureety.com

Remote monitoring of cancer patients is known to improve survival by allowing early reporting and management of adverse events^{1,2}. Based on substantial evidence of their clinical benefits, recent ESMO guidelines recommend the use of digital tools collecting adverse events (AEs) for remote patient monitoring (RPM) in oncology. There is however limited data on the feasibility of digital RPM in real-world settings.

The digital RPM solution Cureety³ has been deployed in French hospitals since 2019. Monitored patients are prompted to complete a weekly PRO questionnaire personalized to their treatment and disease. Based on the adverse events, the Cureety TechCare algorithm computes a «clinical classification» with 4 levels, red, orange, yellow, green (most to least at-risk). The medical team can then prioritize red and orange patients, and provide targeted care if needed.

In the retrospective study presented here, we analyzed the real-world use of Cureety in French hospitals over a 4-year period.

(1) Basch *et al.* Jama 318(2):197-198, 2017; (2) Basch *et al.* Cancer Med. 9(21):7797-7799, 2020; (3) Meghiref *et al.* JMIR Cancer 8(1), 2022

Enrollment



by caregiver Questionnaire at home Critical To be monitored Classification *** algorithm Compromised

Orrect



- High patient and HCP satisfaction
- Algorithm classifications consistent with treatment types
- Adoption increased by French reimbursement program

6457 Patients

Breast

GI tract

Urology

Lung &

thymus

Gynecol.

Hematol

Other


lts

D

S


C

2




professionals in **40 Care centers**

Platform activity over 4.5 years



Characteristic	Ν	%					
All care centers	40	100.0					
Public care centers	22	55.0					
Private care centers	18	45.0					
Size (Number of active HCPs)							
≤ 15	20	50.0					
16-30	16	40.0					
> 30	4	10.0					

Patient & nurse satisfaction



- Good representativity of cancer types and treatments
- Good representativity of care centers in France





335,130 Adverse events

Grade distribution by treatment type									
	Grade 1 Grade 2 Grade	3 Grade 4							
ADC	2926 1	039 158 20							
Chemoth.	140613	3920 8 19 7 561							
Immunoth.	11620 45	14 92 <mark>5</mark> 85							
Targeted th.	31849	85361162 84							
Hormonoth.	27549	8304 654 44							
Combined	34784	108511639 136							
$_{0}$ Radioth.	1262	327 77 11							
-	0% 20% 40% 60%	80% 100%							

Percentage of AE grades

113,692 Questionnaires

Classifications by treatment type

	Correct	Mi	nor		Fragil	e	С	ritical
ADC	480		437				281	85
Chemoth.	25983			16893		1	0177	1985
Immunoth.	6465				186	6	1144	402
Targeted th.	11435				4959		1618	298
Hormonoth.	16629					3	14 4 34	175
Combined	6040			3356			3278	545
Radioth.	912				303	}	140	25
0	% 20)% 4	0%	60%	6	80%	5 1	00%
Percentage of classifications								